Cash, cash equivalents, short-term investments and restricted cash totaled $110.0 million as of September 30, 2024. As of June 30, 2024, cash, cash equivalents, short-term investments and restricted cash totaled $123.0 million. Abeona estimates that its current cash and cash equivalents, short-term investments and restricted cash, as well as its credit facility, are sufficient resources to fund operations into 2026, before accounting for any potential revenue from commercial sales of pz-cel, if approved, or proceeds from the sale of a Priority Review Voucher, if awarded by the FDA.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABEO:
- Abeona Therapeutics announces FDA acceptance of BLA resubmission of pz-cel
- Abeona Therapeutics Inc (ABEO) Q3 Earnings Cheat Sheet
- Abeona Therapeutics announces new employee inducement grants
- Abeona Therapeutics completes Pz-cel BLA resubmission to U.S. FDA
- Abeona Therapeutics announces employment inducement grants
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
